Outcome of Recurrent Uterine Papillary Serous Carcinoma Treated With Platinum-Based Chemotherapy

Mahdi, Haider; Rizzo, Alicia N.; Rose, Peter G.

doi:10.1097/igc.0000000000000382

Cited by 7 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients in our study were subjected to surgical staging. Due to the fact that non-endometrioid tumors have a worse prognosis, all patients, including those in the early stages, should receive adjuvant treatment [22]. However, the efficacy of postoperative adjuvant chemotherapy in these patients remains controversial.…”

Section: Discussionmentioning

confidence: 99%

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Külhan

Kulhan²,

Naykı³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: We aimed to evaluate and compare the clinical and pathological features, diagnosis, treatment, and prognosis of uterine papillary serous carcinoma (UPSC) and clear-cell carcinoma (CC). Material and methods:Thirty-four patients who were operated on for UPSC and CC carcinoma at the İzmir Tepecik Research and Teaching Hospital, between January 1983 and December 2014, were included. Patients were evaluated for the following factors: age, gravidity, parity, preoperative CA-125, tumor size, myometrial and lymphovascular invasion, lymph node tumor metastasis, presence of atypical cells in peritoneal cytology, pathology results, operation types, whether or not they received postoperative adjuvant therapy, prognosis, and death rate. Results:The stage of the disease was the main factor affecting disease-free and the overall survival. Cisplatin-based chemotherapy was partially effective in patients with postoperative recurrence, while postoperative adjuvant radiotherapy proved to be more effective in preventing relapse. Conclusion:The studied parameters generally were concordant with the literature but, due to the relatively small sample size, more comprehensive and multicenter studies are needed to generate valid results.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Külhan

Kulhan²,

Naykı³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…Currently, the most common management strategy for USC is hysterectomy and surgical staging, followed by platinum/paclitaxel-based chemotherapy and radiation therapy [ 3 , 4 , 5 , 6 , 7 ]. However, most USC patients have an unfavorable 5-year survival rate (41%) and poor outcomes due to high recurrence rates and limited effective treatment for recurrence [ 8 , 9 , 10 , 11 ]. Thus, new therapeutic strategies to manage USC are needed.…”

Section: Introductionmentioning

confidence: 99%

Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype

Zhang

Ferri-Borgogno

et al. 2020

Cancers

View full text Add to dashboard Cite

Uterine serous cancer (USC) is an aggressive subtype of endometrial cancer, with poor survival and high recurrence rates. The development of novel and effective therapies specific to USC would aid in its management. However, few studies have focused solely on this rare subtype. The current study demonstrated that the orally bioavailable, investigational new drug and novel imipridone ONC206 suppressed USC cell proliferation and induced apoptosis both in vitro and in vivo. Disruption of the DRD2-mediated p38MAPK/ERK/PGC-1α network by ONC206 led to metabolic reprogramming and suppression of both glycolysis and oxidative phosphorylation. ONC206 also synergized with paclitaxel in reducing USC cell viability. In addition, DRD2 overexpression correlated with poor overall survival in patients. This study provides the first evidence that ONC206 induced metabolic reprogramming in USC cells and is a promising therapeutic agent for USC treatment. These findings support further development of ONC206 as a promising therapeutic agent and improves survival rates in patients with USC.

show abstract

“…UPSC is histologically indistinguishable from high‐grade serous ovarian carcinoma. UPSC tends to have high risk of recurrence and lower survival after recurrence . Prior studies, showed similarities in response to platinum based chemotherapy and applicability of platinum free interval between recurrent UPSC and serous ovarian carcinoma .…”

Section: Introductionmentioning

confidence: 98%

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma

Mahdi

Xiu

Reddy

et al. 2015

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Outcome of Recurrent Uterine Papillary Serous Carcinoma Treated With Platinum-Based Chemotherapy

Cited by 7 publications

References 17 publications

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma

Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma

Contact Info

Product

Resources

About